Screener
R&D at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337935
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $44,265 | $32,415 | $90,405 | $63,329 |
| General and administrative | 13,119 | 9,278 | 24,287 | 18,416 |
| Total operating expenses | 57,384 | 41,693 | 114,692 | 81,745 |
| Loss from operations | (57,384) | (41,693) | (114,692) | (81,745) |
| Other income, net: | ||||
| Interest income | 3,221 | 2,966 | 5,285 | 5,266 |
| Interest expense | — | (60) | — | (128) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Solid Biosciences Inc.'s R&D?
- Solid Biosciences Inc. (SLDB) reported R&D of $44.27M in Q2 2026.
- How has Solid Biosciences Inc.'s R&D changed year-over-year?
- Solid Biosciences Inc.'s R&D increased by 36.6% year-over-year, from $32.42M to $44.27M.
- What is the long-term trend for Solid Biosciences Inc.'s R&D?
- Over 4 years (2021 to 2025), Solid Biosciences Inc.'s R&D has grown at a 24.3% compound annual growth rate (CAGR), from $58.74M to $140.33M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Solid Biosciences Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude